BIO-key International (Nasdaq: BKYI) entered into a warrant inducement agreement with an existing institutional investor covering warrants issued on October 28, 2025. The investor agreed to exercise warrants for 618,334 shares of common stock at a reduced exercise price of $4.06 per share, subject to beneficial ownership limits, generating expected gross proceeds of about $2.5 million before fees.
In consideration, BIO-key will issue the investor 1,236,668 new unregistered warrants with a $4.06 exercise price, exercisable for five years starting on stockholder approval under Nasdaq rules. BIO-key plans to file an SEC registration statement for resale of shares issuable upon exercise of the new warrants.
Loading...
Loading translation...
Positive
Expected gross cash proceeds of approximately $2.5 million from warrant exercises
Immediate issuance of 618,334 shares at $4.06 provides non-debt financing
New warrants for 1,236,668 shares carry a defined five-year term after approval
BIO-key plans SEC registration of resale shares, supporting future liquidity for the investor
Negative
Exercise of existing warrants adds 618,334 new shares of common stock, causing dilution
Potential future dilution from up to 1,236,668 additional shares upon new warrant exercise
New warrants become exercisable only after stockholder approval under Nasdaq rules, adding execution uncertainty
News Explained
The agreement adds potential ownership dilution while expected gross proceeds equal 628.5 days of first-quarter operating cash use.
BIO-key has entered the inducement agreement, but the release describes $2.5 million as expected and makes the New Warrants exercisable only after stockholder approval.
If exercised, the New Warrants would add 1,236,668 common shares; issuing those shares would reduce existing holders’ percentage ownership absent offsetting changes.
On the supplied first-quarter cash-use basis, the expected gross proceeds equal 628.5 days of the last reported operating cash use, while reported cash and equivalents represented 565.1 days on that same basis.
Offering gross vs quarterly operating cash outflow, in days of cash use$2,500,000 / ($358,001 / 90) = [object Object]
Cash and equivalents vs quarterly operating cash outflow, in days of cash use$2,247,984 / ($358,001 / 90) = [object Object]
Market reaction after warrant inducement transaction: BKYI -9.99%
-9.99%$3.7529.0x vol
15m delay
-9.99%Vs previous close
$3.75Last Price
$3.57$4.16Day Range
$3.94MMarket Cap
29.0xRel. Volume
Following this news, BKYI has declined 9.99%, reflecting a notable negative market reaction.
Our momentum scanner has triggered 12 alerts so far, indicating notable trading interest and price volatility.
The stock is currently trading at $3.75.
Trading volume is exceptionally heavy at 29.0x the average, suggesting significant selling pressure.
Historical reactions were mixed: BIO-key’s Nasdaq-compliance announcement registered 43.35%, while t...
Analysis
Historical reactions were mixed: BIO-key’s Nasdaq-compliance announcement registered 43.35%, while the Jordan selection registered -10.53%. That record makes the warrant structure and potential share issuance key factors to watch.
Key Figures
Gross proceeds:$2.5 millionExisting warrant shares:618,334 sharesReduced exercise price:$4.06 per share+3 more
6 metrics
Gross proceeds$2.5 millionWarrant exercise transaction, before fees and expenses
Existing warrant shares618,334 sharesShares exercisable under outstanding warrants
Reduced exercise price$4.06 per shareExercise price for existing and new warrants
New warrant shares1,236,668 sharesUnregistered warrants issued to the investor
New warrant termFive yearsTerm beginning from stockholder approval
Warrants issuedOctober 28, 2025Date of the outstanding warrants
"entered into a warrant inducement agreement with an existing institutional investor"
A warrant inducement agreement is a contract in which a company offers warrants—rights to buy shares at a set price—to a person or group as a sweetener to secure their support, service, or approval for a transaction or role. Investors care because these warrants can increase the total number of shares if exercised, diluting existing ownership and potentially changing the company’s valuation and control dynamics; think of it as paying someone with future stock-buying tickets to get them on board.
beneficial ownership blocker provisionsregulatory
"subject to compliance with beneficial ownership blocker provisions included in the Warrants"
Provisions in corporate charters, shareholder agreements, or regulatory policies that prevent any single person or group from acquiring more than a set percentage of a company’s voting or economic rights without triggering restrictions or forced actions. They matter to investors because they can block concentration of control, limit takeover attempts or large stake builds, and change how shares trade or how votes are cast—like a speed governor on a car that keeps one driver from going too fast.
placement agentfinancial
"Maxim Group LLC is acting as the exclusive Placement Agent"
A placement agent is a professional or firm that helps organizations raise money from investors, such as individuals, institutions, or funds. They act like matchmakers, connecting those seeking investments with the right investors and guiding the process to ensure successful funding. For investors, they can provide access to exclusive opportunities and help navigate complex fundraising efforts.
registration statementregulatory
"agreed to file a registration statement with the Securities and Exchange Commission"
A registration statement is a formal document that companies file with a government agency to offer new shares of stock to the public. It provides essential information about the company's finances, operations, and risks, helping investors make informed decisions. Think of it as a detailed product description that ensures transparency and trust before buying into a company.
HOLMDEL, N.J., Aug. 11, 2026 (GLOBE NEWSWIRE) -- BIO-key International, Inc. (Nasdaq: BKYI), a global innovator in Identity and Access Management (IAM) and biometric authentication solutions, today announced it has entered into a warrant inducement agreement with an existing institutional investor for the exercise of certain outstanding warrants that the Company issued on October 28, 2025 (the “Warrants”). Pursuant to the warrant inducement agreement, the investor has agreed to exercise the Warrants to purchase an aggregate of 618,334 shares of the Company's common stock at a reduced exercise price of $4.06 per share, subject to compliance with beneficial ownership blocker provisions included in the Warrants.The gross proceeds from the exercise of the Warrants are expected to be approximately $2.5 million, prior to deducting placement agent fees and estimated offering expenses.
Maxim Group LLC is acting as the exclusive Placement Agent for the transaction.
In consideration for the exercise of the Warrants, the Company also agreed to issue to the investor unregistered warrants to purchase an aggregate of 1,236,668 shares of the Company's common stock with an exercise price of $4.06 per share (the “New Warrants”).The New Warrants will be exercisable upon the receipt of stockholder approval of the exercise of the New Warrants in accordance with applicable Nasdaq rules and have a term of exercise equal to five years from the date of such stockholder approval.The Company has agreed to file a registration statement with the Securities and Exchange Commission covering the resale of the shares of common stock issuable upon exercise of the New Warrants. This press release shall not constitute an offer to sell or a solicitation of an offer to buy any of the securities described herein, nor shall there be any sale of these securities in any state or other jurisdiction in which such offer, solicitation or sale would be unlawful prior to the registration or qualification under the securities laws of any such state or other jurisdiction.
About BIO-key International, Inc. (www.bio-key.com) BIO-key International (NASDAQ: BKYI) is a global provider of Identity and Access Management (IAM) and biometric authentication solutions, protecting more than 40 million users worldwide. BIO-key’s PortalGuard platform delivers enterprise-grade Multi-Factor Authentication, Single Sign-On, passwordless authentication, biometric identity verification, and Identity-Bound Biometrics (IBB), helping organizations strengthen security while simplifying user access across cloud and on-premises environments.
BIO-key Safe Harbor Statement All statements contained in this press release other than statements of historical facts are “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. These statements are based on current expectations and assumptions and are subject to risks and uncertainties that could cause actual results to differ materially from those expressed or implied. BIO-key undertakes no obligation to update any forward-looking statements except as required by applicable law.
Investor Contacts William Jones, David Collins Catalyst IR BKYI@catalyst-ir.com or 212-924-9800
FAQ
What is the value of BIO-key International’s (BKYI) August 11, 2026 warrant inducement transaction?
The transaction is expected to generate approximately $2.5 million in gross proceeds. According to BIO-key, this comes from the investor’s agreed exercise of warrants for 618,334 shares at a reduced exercise price of $4.06 per share, before fees and expenses.
How many BIO-key (BKYI) shares are involved in the August 2026 warrant inducement agreement?
The investor will exercise warrants for 618,334 shares and receive new warrants for 1,236,668 shares. According to BIO-key, all shares relate to common stock at a $4.06 exercise price, subject to ownership blockers and future stockholder approval.
What is the exercise price and term of the new BIO-key (BKYI) warrants issued in August 2026?
The new warrants have a $4.06 per share exercise price and a five-year term. According to BIO-key, they become exercisable only after stockholders approve their exercise under applicable Nasdaq rules, starting the five-year exercise period from that approval date.
When will the new BIO-key (BKYI) warrants from the August 11, 2026 transaction become exercisable?
The new warrants become exercisable upon receipt of required stockholder approval. According to BIO-key, stockholder approval must comply with applicable Nasdaq rules, and the new warrants will then remain exercisable for five years from the date that approval is obtained.
How might the August 2026 warrant inducement affect BIO-key (BKYI) shareholder dilution?
The immediate exercise adds 618,334 shares, increasing the share count. According to BIO-key, the investor also receives new warrants for 1,236,668 shares, which, if later exercised, would further increase outstanding shares and contribute to additional dilution.
Will BIO-key (BKYI) register the shares underlying the new August 2026 warrants?
Yes, BIO-key has agreed to file a registration statement with the SEC for resale. According to BIO-key, this registration will cover the shares of common stock issuable upon exercise of the new warrants, facilitating potential future secondary market transactions.
